Hospital
Ascension Borgess Hospital
Ascension Borgess Hospital was paid $43.08M by Medicaid between Jan 2018 and Dec 2024, across 454 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 21% of everything it billed.
33Billing provider infoASCENSION BORGESS HOSPITAL
KALAMAZOO, MI 49048
KALAMAZOO, MI 49048
33aNPI1568416311assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$43.08M
24GClaims1,309,883
24DCodes billed454
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#28 of 86
Median peer was paid$21.55M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HOUGHTON, MARINA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 180,808 | $5.97M | |
| 2019 | 198,048 | $6.29M | |
| 2020 | 172,510 | $5.51M | |
| 2021 | 231,143 | $7.69M | |
| 2022 | 223,874 | $6.85M | |
| 2023 | 195,744 | $6.55M | |
| 2024incomplete | 107,756 | $4.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 21% | 183,442 | 153,309 | $8.87M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 23,777 | 21,486 | $7.57M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 24,848 | 23,009 | $4.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 27,195 | 25,451 | $3.44M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.3% | 15,809 | 14,115 | $1.40M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 3,661 | 3,609 | $777K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.7% | 1,494 | 1,464 | $753K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 5,333 | 5,155 | $748K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 23,338 | 7,682 | $572K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,574 | 11,027 | $416K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,444 | 9,784 | $412K |
| 82947 | <1% | 10,925 | 7,733 | $409K |
442 more codes
| G0378 | Hospital observation service, per hour | <1% | 4,605 | $405K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,822 | $399K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,345 | $390K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 7,662 | $390K |
| 93458 | <1% | 344 | $341K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,188 | $331K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,158 | $329K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,079 | $301K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 589 | $278K |
| 93975 | <1% | 2,128 | $249K | |
| A0425 | Ground mileage, per statute mile | <1% | 3,110 | $249K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 727 | $247K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,597 | $247K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 390 | $240K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,692 | $209K |
| 59025 | Fetal non-stress test | <1% | 2,456 | $204K |
| 82465 | <1% | 5,536 | $200K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,258 | $198K |
| Q3014 | Telehealth originating site facility fee | <1% | 11,575 | $198K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 750 | $189K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,648 | $184K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,876 | $179K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,267 | $178K |
| 76830 | Ultrasound, transvaginal | <1% | 3,045 | $177K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 12,153 | $172K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,996 | $163K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,186 | $158K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,200 | $156K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,136 | $156K |
| 76801 | <1% | 2,697 | $156K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,318 | $146K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14,797 | $140K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,061 | $134K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,615 | $132K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,034 | $130K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,286 | $127K |
| 80053 | Comprehensive metabolic panel | <1% | 49,994 | $125K |
| 95910 | <1% | 863 | $123K | |
| 97161 | <1% | 2,496 | $121K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,448 | $120K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,601 | $115K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,644 | $114K |
| 94060 | <1% | 714 | $104K | |
| 20610 | <1% | 784 | $104K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,557 | $101K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,677 | $99K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 551 | $97K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,450 | $94K |
| 97162 | <1% | 2,004 | $92K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,906 | $82K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 470 | $82K |
| 80061 | Lipid panel | <1% | 6,978 | $81K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,535 | $79K |
| 93971 | <1% | 1,379 | $76K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 5,090 | $73K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,602 | $72K |
| 93017 | <1% | 2,114 | $69K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,070 | $68K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,399 | $66K |
| 86900 | <1% | 4,030 | $60K | |
| 71250 | <1% | 1,036 | $60K | |
| 72141 | <1% | 448 | $59K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 949 | $58K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,886 | $57K |
| 90670 | <1% | 1,981 | $56K | |
| 95908 | <1% | 368 | $54K | |
| 70496 | <1% | 384 | $51K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,356 | $50K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,353 | $49K |
| 90686 | <1% | 5,126 | $49K | |
| 97165 | <1% | 1,097 | $43K | |
| 87797 | <1% | 2,668 | $41K | |
| 77066 | Tomosynthesis, mammo | <1% | 673 | $40K |
| 73221 | <1% | 335 | $40K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,772 | $39K |
| 76641 | <1% | 666 | $39K | |
| 72100 | <1% | 1,815 | $38K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 251 | $35K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,802 | $33K |
| 73630 | <1% | 4,945 | $32K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,039 | $32K |
| 76642 | <1% | 781 | $30K | |
| 87480 | <1% | 2,668 | $28K | |
| 87510 | <1% | 2,664 | $28K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 709 | $28K |
| 76536 | <1% | 551 | $28K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,800 | $28K |
| 81513 | <1% | 978 | $27K | |
| 74246 | <1% | 277 | $27K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,768 | $25K |
| 73610 | <1% | 3,275 | $25K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 100 | $25K |
| 82607 | <1% | 3,828 | $24K | |
| 99406 | <1% | 1,708 | $23K | |
| 97803 | <1% | 1,585 | $22K | |
| 72158 | <1% | 120 | $22K | |
| 74018 | <1% | 1,599 | $21K | |
| 73130 | <1% | 2,833 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 581 | $21K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,389 | $21K |
| 43235 | <1% | 49 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,302 | $20K |
| 93296 | <1% | 992 | $20K | |
| 73030 | <1% | 2,646 | $19K | |
| 90674 | <1% | 775 | $18K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,844 | $18K |
| 77065 | Tomosynthesis, mammo | <1% | 405 | $18K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 463 | $18K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 26 | $18K |
| 96127 | <1% | 3,380 | $18K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 886 | $17K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,479 | $17K |
| 73110 | <1% | 2,248 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 761 | $16K |
| 87430 | <1% | 2,931 | $16K | |
| 82728 | <1% | 2,546 | $16K | |
| 81025 | <1% | 18,218 | $16K | |
| 73562 | <1% | 2,285 | $15K | |
| 83880 | <1% | 3,481 | $15K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 236 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,335 | $14K |
| 88307 | <1% | 380 | $14K | |
| 84439 | <1% | 3,665 | $14K | |
| 72110 | <1% | 685 | $14K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,086 | $14K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 360 | $14K |
| 84481 | <1% | 1,718 | $14K | |
| 95909 | <1% | 91 | $13K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 44 | $13K |
| 83921 | <1% | 1,305 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,397 | $13K |
| 87481 | <1% | 1,092 | $13K | |
| 73560 | <1% | 1,292 | $13K | |
| 84478 | <1% | 5,590 | $12K | |
| 90620 | <1% | 228 | $12K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 62 | $12K |
| 90677 | <1% | 227 | $11K | |
| 97602 | <1% | 124 | $11K | |
| 73140 | <1% | 1,227 | $11K | |
| 87186 | <1% | 3,973 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,595 | $11K |
| 70498 | <1% | 368 | $10K | |
| 86803 | <1% | 1,729 | $10K | |
| 73502 | <1% | 1,763 | $10K | |
| 97597 | <1% | 108 | $10K | |
| 64721 | <1% | 13 | $10K | |
| 81001 | <1% | 26,504 | $10K | |
| 83540 | <1% | 3,424 | $10K | |
| 84702 | <1% | 3,004 | $10K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 872 | $10K |
| 93226 | <1% | 164 | $10K | |
| 83718 | <1% | 5,482 | $10K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 866 | $9K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 24 | $9K |
| 85610 | <1% | 10,622 | $9K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,975 | $9K |
| 83690 | <1% | 11,416 | $9K | |
| 84484 | <1% | 12,635 | $9K | |
| 83735 | <1% | 7,800 | $9K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 34 | $8K |
| 86850 | <1% | 3,966 | $8K | |
| 85027 | <1% | 5,698 | $8K | |
| 87631 | <1% | 659 | $8K | |
| 70486 | <1% | 124 | $8K | |
| 83550 | <1% | 1,956 | $8K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 40 | $8K |
| 81000 | <1% | 4,281 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 825 | $8K |
| 72040 | <1% | 924 | $8K | |
| 87340 | <1% | 2,278 | $8K | |
| 87634 | <1% | 223 | $8K | |
| 90688 | <1% | 495 | $8K | |
| 95819 | <1% | 64 | $8K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 362 | $8K |
| 96161 | <1% | 668 | $8K | |
| 84425 | <1% | 789 | $8K | |
| 87486 | <1% | 507 | $7K | |
| 87581 | <1% | 507 | $7K | |
| 90734 | <1% | 575 | $7K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $7K |
| 82746 | <1% | 935 | $7K | |
| 87070 | <1% | 2,039 | $7K | |
| 93970 | <1% | 72 | $7K | |
| 80074 | <1% | 415 | $7K | |
| 72050 | <1% | 316 | $7K | |
| 95811 | <1% | 14 | $7K | |
| 99496 | <1% | 111 | $7K | |
| 87077 | <1% | 2,466 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $6K |
| 96376 | <1% | 3,990 | $6K | |
| 93225 | <1% | 106 | $6K | |
| 90474 | <1% | 1,255 | $6K | |
| 83525 | <1% | 1,051 | $6K | |
| 86592 | <1% | 2,676 | $6K | |
| 82043 | <1% | 1,924 | $5K | |
| 86140 | <1% | 3,372 | $5K | |
| 86780 | <1% | 717 | $5K | |
| 83655 | <1% | 802 | $5K | |
| 84403 | <1% | 360 | $5K | |
| 87641 | <1% | 282 | $4K | |
| 86003 | <1% | 84 | $4K | |
| 77080 | <1% | 71 | $4K | |
| 20611 | <1% | 26 | $4K | |
| 88304 | <1% | 1,290 | $4K | |
| 83001 | <1% | 426 | $4K | |
| 20550 | <1% | 30 | $4K | |
| 86762 | <1% | 1,109 | $4K | |
| 71271 | <1% | 67 | $4K | |
| 76770 | <1% | 69 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 56 | $4K |
| 93299 | <1% | 196 | $4K | |
| 88342 | <1% | 315 | $4K | |
| 72070 | <1% | 199 | $4K | |
| 84703 | <1% | 1,297 | $3K | |
| 82670 | <1% | 231 | $3K | |
| 93298 | <1% | 194 | $3K | |
| 75574 | <1% | 39 | $3K | |
| 87088 | <1% | 1,331 | $3K | |
| 93351 | <1% | 12 | $3K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,557 | $3K |
| 87210 | <1% | 3,331 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 290 | $3K |
| 85730 | <1% | 6,304 | $3K | |
| 97035 | <1% | 523 | $3K | |
| 93880 | <1% | 30 | $3K | |
| 90732 | <1% | 27 | $3K | |
| 86038 | <1% | 1,006 | $3K | |
| 84146 | <1% | 319 | $3K | |
| 90651 | <1% | 54 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $3K |
| 82950 | <1% | 1,151 | $3K | |
| 73080 | <1% | 431 | $3K | |
| 87081 | <1% | 970 | $3K | |
| 0240U | <1% | 1,121 | $3K | |
| 73700 | <1% | 53 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,220 | $3K |
| 70491 | <1% | 25 | $2K | |
| 87150 | <1% | 148 | $2K | |
| 82784 | <1% | 355 | $2K | |
| 82747 | <1% | 396 | $2K | |
| 90716 | <1% | 191 | $2K | |
| 86235 | <1% | 113 | $2K | |
| 97802 | <1% | 93 | $2K | |
| 86901 | <1% | 4,022 | $2K | |
| 85651 | <1% | 1,838 | $2K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 12 | $2K |
| 95806 | <1% | 24 | $2K | |
| 82270 | <1% | 141 | $2K | |
| 94726 | <1% | 349 | $2K | |
| 72156 | <1% | 13 | $2K | |
| 87899 | <1% | 248 | $2K | |
| 93922 | <1% | 355 | $2K | |
| 73590 | <1% | 308 | $2K | |
| 64400 | <1% | 13 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 86 | $2K |
| 86703 | <1% | 850 | $2K | |
| 99495 | <1% | 27 | $2K | |
| 81002 | <1% | 1,611 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,274 | $2K |
| 11719 | <1% | 100 | $1K | |
| 80076 | <1% | 678 | $1K | |
| 85652 | <1% | 1,568 | $1K | |
| 99493 | <1% | 38 | $1K | |
| 83521 | <1% | 80 | $1K | |
| 73564 | <1% | 457 | $1K | |
| 95886 | <1% | 2,794 | $1K | |
| 84550 | <1% | 699 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,793 | $1K |
| 71101 | <1% | 69 | $1K | |
| 85379 | <1% | 2,443 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 46 | $1K |
| 86431 | <1% | 456 | $1K | |
| 86787 | <1% | 386 | $1K | |
| 10060 | <1% | 12 | $1K | |
| 84165 | <1% | 176 | $954.90 | |
| 73090 | <1% | 124 | $944.69 | |
| 88143 | <1% | 96 | $941.04 | |
| 85018 | <1% | 1,104 | $843.46 | |
| 92551 | <1% | 117 | $773.86 | |
| 87254 | <1% | 61 | $773.66 | |
| 83605 | <1% | 4,343 | $751.00 | |
| 86480 | <1% | 25 | $746.13 | |
| 82550 | <1% | 1,423 | $739.35 | |
| 90682 | <1% | 14 | $725.81 | |
| 82570 | <1% | 353 | $707.53 | |
| 82565 | <1% | 693 | $684.47 | |
| 82962 | <1% | 3,059 | $663.25 | |
| G0008 | Administration of influenza virus vaccine | <1% | 147 | $657.18 |
| 83970 | <1% | 29 | $648.68 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 63 | $633.85 |
| 82785 | <1% | 75 | $625.78 | |
| 84100 | <1% | 1,078 | $614.40 | |
| 86376 | <1% | 91 | $612.38 | |
| 83516 | <1% | 109 | $582.08 | |
| 17110 | <1% | 14 | $556.91 | |
| S0166 | Injection, olanzapine, 2.5 mg | <1% | 16 | $552.57 |
| 84156 | <1% | 380 | $541.92 | |
| 97760 | <1% | 16 | $535.98 | |
| 90715 | <1% | 2,709 | $533.26 | |
| 90480 | <1% | 14 | $523.74 | |
| 82150 | <1% | 184 | $518.34 | |
| 87147 | <1% | 303 | $512.99 | |
| 87040 | <1% | 2,159 | $463.70 | |
| 87338 | <1% | 50 | $462.23 | |
| 86334 | <1% | 49 | $453.34 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,428 | $445.74 |
| 86225 | <1% | 84 | $402.86 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,336 | $383.45 |
| 90473 | <1% | 32 | $373.19 | |
| 97804 | <1% | 77 | $354.96 | |
| 90661 | <1% | 47 | $344.82 | |
| 36592 | <1% | 144 | $336.09 | |
| 90461 | <1% | 117 | $308.11 | |
| 97116 | <1% | 33 | $291.29 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 134 | $291.22 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 175 | $276.05 |
| 83002 | <1% | 24 | $274.82 | |
| 58300 | <1% | 15 | $271.95 | |
| 90647 | <1% | 1,510 | $271.00 | |
| 72170 | <1% | 38 | $232.87 | |
| 82533 | <1% | 26 | $230.60 | |
| 83615 | <1% | 128 | $222.53 | |
| 90672 | <1% | 38 | $216.38 | |
| 96160 | <1% | 15 | $205.80 | |
| 12001 | <1% | 239 | $201.29 | |
| 80143 | <1% | 1,288 | $200.01 | |
| 36416 | <1% | 1,260 | $192.71 | |
| 80179 | <1% | 1,229 | $189.11 | |
| 88300 | <1% | 28 | $152.26 | |
| 82525 | <1% | 26 | $151.62 | |
| 94010 | <1% | 12 | $137.86 | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,992 | $136.90 |
| 76942 | <1% | 1,309 | $134.13 | |
| 69209 | <1% | 48 | $129.11 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 13 | $111.36 |
| 81003 | <1% | 252 | $106.02 | |
| 86200 | <1% | 12 | $97.41 | |
| J3490 | Unclassified drugs | <1% | 4,339 | $93.50 |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 74 | $87.00 |
| 86308 | <1% | 53 | $78.67 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 51 | $73.70 |
| 83695 | <1% | 44 | $68.62 | |
| 76870 | <1% | 37 | $68.30 | |
| 86706 | <1% | 13 | $66.67 | |
| 82248 | <1% | 29 | $65.46 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,662 | $64.81 |
| 87075 | <1% | 39 | $61.44 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,055 | $60.05 |
| 99152 | <1% | 1,309 | $59.71 | |
| 69210 | <1% | 26 | $56.63 | |
| 84155 | <1% | 27 | $50.64 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,025 | $40.13 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 694 | $39.41 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 805 | $39.10 |
| 87280 | <1% | 25 | $37.65 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,805 | $37.44 |
| 86364 | <1% | 14 | $35.78 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,463 | $33.28 |
| 94729 | <1% | 656 | $33.08 | |
| 94690 | <1% | 30 | $32.38 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 989 | $31.10 |
| 90714 | <1% | 482 | $30.39 | |
| 87640 | <1% | 12 | $29.05 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,332 | $28.36 |
| 99153 | Mod sedat endo service >5yrs | <1% | 822 | $24.95 |
| 90656 | <1% | 27 | $19.77 | |
| 80164 | <1% | 15 | $17.02 | |
| 82010 | <1% | 65 | $14.66 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,714 | $12.72 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,872 | $10.42 |
| 87205 | <1% | 12 | $8.84 | |
| 82140 | <1% | 37 | $8.67 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,203 | $8.11 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,481 | $3.38 |
| 85347 | <1% | 83 | $2.82 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,943 | $2.75 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,374 | $2.57 |
| 84520 | <1% | 15 | $2.48 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,864 | $1.36 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 15 | $1.20 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 27 | $0.41 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,089 | $0.07 |
| C1769 | Guide wire | <1% | 2,354 | $0.05 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,882 | $0.05 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,952 | $0.04 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,050 | $0.03 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,193 | $0.03 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,505 | $0.03 |
| 94760 | <1% | 58 | $0.03 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,127 | $0.03 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,539 | $0.02 |
| 99173 | <1% | 121 | $0.02 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 241 | $0.01 |
| 82075 | <1% | 36 | $0.01 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 39 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 1,713 | $0.00 |
| 90680 | 0% | 1,539 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 772 | $0.00 |
| 90723 | 0% | 1,716 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 236 | $0.00 |
| 90696 | 0% | 141 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 107 | $0.00 |
| A4355 | Irrigation tubing set for continuous bladder irrigation through a three-way indwelling foley catheter, each | 0% | 132 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 124 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 14 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 130 | $0.00 |
| 12002 | 0% | 12 | $0.00 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 24 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 27 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 14 | $0.00 |
| 84270 | 0% | 13 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 43 | $0.00 |
| 84132 | 0% | 14 | $0.00 | |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | 0% | 15 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 562 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 244 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 1,029 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 280 | $0.00 |
| 64447 | 0% | 12 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 439 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 873 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,053 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 25 | $0.00 |
| 93321 | 0% | 182 | $0.00 | |
| 90707 | 0% | 248 | $0.00 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 188 | $0.00 |
| 93325 | 0% | 162 | $0.00 | |
| 90633 | 0% | 871 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,482 | $0.00 |
| G9002 | Coordinated care fee, maintenance rate | 0% | 72 | $0.00 |
| 90710 | 0% | 176 | $0.00 | |
| 82800 | 0% | 13 | $0.00 | |
| 90700 | 0% | 289 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 141 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 73 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 74 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 29 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 34 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 70 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 64 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 31 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOUGHTON, MARINA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ascension Medical Group Promed | Kalamazoo, MI | $10.60M |
| Ascension Medical Group Promed | Portage, MI | $7.97M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $6.88M |
| Ascension Borgess Allegan Hospital | Allegan, MI | $6.03M |
| Ascension Borgess Hospital | Plainwell, MI | $4.84M |
| Ascension Borgess Allegan Hospital | Allegan, MI | $3.71M |
| Ascension Borgess Hospital | Plainwell, MI | $3.71M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $2.70M |
| Ascension Medical Group Promed | Kalamazoo, MI | $2.55M |
| Ascension Medical Group Promed | Portage, MI | $2.07M |
| Ascension Medical Group Promed | Portage, MI | $1.64M |
| Ascension Borgess Lee Hospital | Dowagiac, MI | $1.58M |
| Ascension Borgess Hospital | Portage, MI | $1.22M |
| Ascension Borgess Allegan Hospital | Gobles, MI | $298K |
| Ascension Borgess Allegan Hospital | Otsego, MI | $294K |
| Ascension Borgess Allegan Hospital | Fennville, MI | $246K |
| Ascension Borgess Hospital | Kalamazoo, MI | $91K |
| Ascension Borgess Allegan Hospital | Allegan, MI | $55K |
| Ascension Borgess Allegan Hospital | Allegan, MI | $43K |
| Ascension Borgess Hospital | Kalamazoo, MI | $40K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.